
Opinion|Videos|July 29, 2024
ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the emerging data presented at ASCO 2024 on the phase 1 study of IMC-F106C (brenetafusp), a PRAME x CD3 ImmTAC bispecific protein in post-checkpoint cutaneous melanoma. (
Abstract )
1. What was the objective of this study?
2. How was this study designed/what methodology was used?
3. What results were presented?
i. Patient population: N=46
A. Prior therapy: 100% anti-PD1, 88% anti-CTLA4, 25% BRAF/MEK inhibitors
ii. Primary objectives:
A. Safety
B. Selection of recommended dose
iii. Secondary objectives:
A. Efficacy
B. ctDNA response
- Please provide your key takeaways from this study. How might a PRAME x CD3 bispecific product impact the management of melanoma in the future?
Advertisement
Related to this article

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.

The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5

